SYK vs. BSX, BDX, DXCM, RMD, ELV, SNY, MDT, ISRG, VRTX, and REGN
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Boston Scientific (BSX), Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), Elevance Health (ELV), Sanofi (SNY), Medtronic (MDT), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "medical" sector.
Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Stryker currently has a consensus target price of $365.94, indicating a potential upside of 9.34%. Boston Scientific has a consensus target price of $75.32, indicating a potential upside of 0.90%. Given Stryker's higher probable upside, equities research analysts clearly believe Stryker is more favorable than Boston Scientific.
Stryker has a net margin of 16.03% compared to Boston Scientific's net margin of 12.06%. Stryker's return on equity of 23.05% beat Boston Scientific's return on equity.
Boston Scientific received 108 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.33% of users gave Boston Scientific an outperform vote while only 64.51% of users gave Stryker an outperform vote.
Stryker has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
77.1% of Stryker shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 5.9% of Stryker shares are held by insiders. Comparatively, 0.5% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, Boston Scientific had 11 more articles in the media than Stryker. MarketBeat recorded 22 mentions for Boston Scientific and 11 mentions for Stryker. Stryker's average media sentiment score of 0.77 beat Boston Scientific's score of 0.55 indicating that Stryker is being referred to more favorably in the media.
Summary
Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
